AFM
CABA icon

Anson Funds Management’s Cabaletta Bio CABA Stock Holding History

Anson Funds Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,822,830
Closed -$2.77M – 121
2025
Q2 		$2.77M Buy
+1,822,830
New +$2.84M 0.4% 41

Other funds holding CABA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

Anson Funds Management's CABA Position: Q3 2025 in Review

Anson Funds Management sold out of Cabaletta Bio (CABA) in Q3 2025, closing a stake of 1,822,830 shares — an estimated $2.77M sold.

Anson Funds Management first reported a position in CABA in Q2 2025 and held it in 1 quarter. The position peaked at $2.77M in Q2 2025. 75 funds tracked by Wall St. Rank hold CABA as of Q3 2025.

  • Anson Funds Management reported no remaining Cabaletta Bio position as of Q3 2025 after selling out during the quarter.
  • Anson Funds Management sold 1,822,830 Cabaletta Bio shares in Q3 2025, an estimated $2.77M.
  • Anson Funds Management first reported a position in Cabaletta Bio in Q2 2025 and held it in 1 quarter.
  • Anson Funds Management's Cabaletta Bio position peaked at $2.77M in Q2 2025.
  • 75 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2025.

Based on Anson Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.